Name: | Hexobarbital |
---|---|
PubChem Compound ID: | 10464307 |
Description: | A barbiturate that is effective as a hypnotic and sedative. |
Molecular formula: | C6H10O |
Molecular weight: | 101.161 g/mol |
Name: | Hexobarbital |
---|---|
Name (isomeric): | DB01355 |
Drug Type: | small molecule |
Description: | A barbiturate that is effective as a hypnotic and sedative. |
Synonyms: |
Methexenyl; 5-(1-cyclohexen-1-yl)-1,5-dimethylbarbituric acid; Hexobarbitone; Methylhexabital
|
Brand: | Evipan, Cyclopal, Citopan, Sombulex, Barbidorm, Evipal, Cyclopan, Somnalert, Sombucaps, Noctivane |
Category: | GABA Modulators, Hypnotics and Sedatives, Barbiturates, Adjuvants |
CAS number: | 56-29-1 |
Indication: | For the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. |
---|---|
Pharmacology: |
Hexobarbital is a barbiturate derivative having hypnotic and sedative effects. It was used in the 1940s-1950s as an agent for inducing anesthesia for surgery and has a relatively fast onset of effects and short duration of action. However it can be difficult to control the depth of anesthesia with hexobarbital which makes it quite dangerous, and it...
show more » |
Mechanism of Action: | Hexobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABA-A receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. |
Protein binding: | 25% |
Biotransformation: | Hepatic. |
Toxicity: | Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death. |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|